Cambrex Signs Agreement To Acquire ProSyntest AS

Date : 01/07/2008 @ 2:00PM
Source : PR Newswire
Stock : Cambrex Cp (CBM)
Quote : 5.2  0.61 (13.29%) @ 8:00PM
<< BackQuote Chart Financials

 



Cambrex Signs Agreement To Acquire ProSyntest AS

EAST RUTHERFORD, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Cambrex Karlskoga AB, a subsidiary of Cambrex Corporation (NYSE:CBM), is pleased to announce it has entered into a purchase agreement for all of the stock of ProSyntest AS, a privately held active pharmaceutical ingredients ("API") research and development company. ProSyntest employs approximately twenty five chemists located within the Tallinn Technology Park in Tallinn, Estonia. ProSyntest, formed in 1990 as a spin off from Tallinn University of Technology, has strengths in cost effective chemical route selection and sample generation, rapid scale up of products at kilo lab scale, as well as chiral and organometallic chemistries.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

"Cambrex Karlskoga has successfully worked with the ProSyntest chemists for the past fifteen years, and the acquisition of the business is a natural extension of our long standing relationship. ProSyntest, located in Eastern Europe, will enable Cambrex to more effectively compete in the high growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives," commented Steven Klosk, Executive Vice President & COO of Cambrex Corporation.

The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex intends to add more process and analytical chemists at the site and continue early API development work in Tallinn for scale up at Karlskoga and the other Cambrex manufacturing facilities.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com/.

http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO

http://photoarchive.ap.org/

DATASOURCE: Cambrex Corporation

CONTACT: Gregory P. Sargen, Vice President & CFO of Cambrex,

+1-201-804-3055,

Web site: http://www.cambrex.com/

Company News On-Call: http://www.prnewswire.com/comp/134219.html

<< Back


Cambrex Cp Historical Chart Cambrex Cp Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
32 site:2us 081007 04:32 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )